Market Overview

UPDATE: Cantor Fitzgerald Initiates Hold, $27 PT on Health Net on Lower Cost, Restructuring and Sales

Share:
Related HNT
Probes Reporter Provides Updates On Six SEC Investigations
UBS Has Had Enough: Centene Upgraded To Buy On 'Underappreciated Opportunities'

Cantor Fitzgerald initiates its coverage on Health Net (NYSE: HNT) with a Buy rating and a price target of $27.

Cantor Fitzgerald says, "Although 1Q:12 was marred by $67 million of adverse development, several things could drive better results in 2013, in our opinion, such as lower costs, restructuring, and ramping sales of lower-cost plans. The stock's valuation is not high by historical standards, or in comparison with its peers, but catalysts are not easy to find, and with all the economic headwinds and uncertainty about the managed care outlook in general, we are not inclined to step up to the stock absent some evidence that enrollment is once again trending up."

HNT closed at $24.84 on Tuesday.

Latest Ratings for HNT

DateFirmActionFromTo
Aug 2015BMO CapitalMaintainsMarket Perform
Aug 2015BarclaysMaintainsUnderweight
Jul 2015Goldman SachsDowngradesBuyNeutral

View More Analyst Ratings for HNT
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Initiation Intraday Update Analyst Ratings

 

Related Articles (HNT)

Get Benzinga's Newsletters